Effectiveness of and Financial Returns to Voluntary Medical Male Circumcision for HIV Prevention in South Africa: An Incremental Cost-Effectiveness Analysis

1. WHO and UNAIDS. New data on male circumcision and HIV prevention: policy and programme implications. WHO/UNAIDS Technical Consultation, Male Circumcision and HIV Prevention: Research Implications for Policy and Programming. Montreux, 6–8 March 2007. Geneva: WHO and UNAIDS; 2007. http://libdoc.who.int/publications/2007/9789241595988_eng.pdf

2. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369(9562): 643–56. doi: 10.1016/S0140-6736(07)60312-2 17321310

3. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11): e298. doi: 10.1371/journal.pmed.0020298 16231970

4. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562): 657–66. doi: 10.1016/S0140-6736(07)60313-4 17321311

5. Schwartländer B, Stover J, Hallett T, Atun R, Avila C, Gouws E, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011;377(9782): 2031–41. doi: 10.1016/S0140-6736(11)60702-2 21641026

6. WHO and UNAIDS. Joint strategic action framework to accelerate the scale-up of voluntary medical male circumcision for HIV prevention in eastern and southern Africa 2012–2016. Geneva: UNAIDS; 2011. http://whqlibdoc.who.int/unaids/2011/JC2251E_eng.pdf?ua=1

7. Nagelkerke NJD, Moses S, de Vlas SJ, Bailey RC. Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa. BMC Infect Dis. 2007;7:16. doi: 10.1186/1471-2334-7-16 17355625

8. White RG, Glynn JR, Orroth KK, Freeman EE, Bakker R, Weiss HA, et al. Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when? AIDS. 2008;22(14): 1841–50. doi: 10.1097/QAD.0b013e32830e0137 18753931

9. Kahn JG, Marseille E, and Auvert B. Cost-effectiveness of male circumcision for HIV prevention in a South African setting. PLoS Med. 2008;3(12): e517. doi: 10.1371/journal.pmed.0030517

10. Auvert B, Marseille E, Korenromp EL, Lloyd-Smith J, Sitta R, Taljaard D, et al. Estimating the resources needed and savings anticipated from roll-out of adult male circumcision in sub-Saharan Africa. PLoS Med. 2008;3(8): e2679. doi: 10.1371/journal.pone.0002679

11. Njeuhmeli E, Forsythe S, Reed J, Opuni M, Bollinger L, Heard N, et al. Voluntary medical male circumcision: modeling the impact and cost of expanding male circumcision for HIV prevention in eastern and southern Africa. PLoS Med. 2011;8(11): e1001132. doi: 10.1371/journal.pmed.1001132 22140367

12. Hallett TB, Singh K, Smith JA, White RG, Abu-Raddad LJ, Garnett GP. Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS ONE. 2008;3(5): e2212. doi: 10.1371/journal.pone.0002212 18493593

13. World Health Organization (WHO). WHO progress brief: voluntary medical male circumcision for HIV prevention in 14 priority countries in East and Southern Africa—July 2015. Geneva: WHO; 2015. http://www.who.int/hiv/pub/malecircumcision/brief2015/en.

14. Sgaier SK, Reed JB, Thomas A, Njeuhmeli E. Achieving the HIV prevention impact of voluntary medical male circumcision: lessons and challenges for managing programs. PLoS Med. 2014;11(5): e1001641. doi: 10.1371/journal.pmed.1001641 24800840

15. Bollinger L, Adesina A, Forsythe S, Godbole R, Reuben E, Njeuhmeli E. Cost Drivers for Voluntary Medical Male Circumcision Using Primary Source Data from Sub-Saharan Africa. PLoS ONE. 2014;9(5): e84701. doi: 10.1371/journal.pone.0084701 24802593

16. Ashengo TA, Hatzold K, Mahler H, Rock A, Kanagat N, Magalona S, et al. Voluntary medical male circumcision (VMMC) in Tanzania and Zimbabwe: service delivery intensity and modality and their influence on the age of clients. PLoS ONE. 2014;9(5): e83642. doi: 10.1371/journal.pone.0083642 24801882

17. Hatzold K, Mavhu W, Jasi P, Chatora K, Cowan F, Taruberekera N. Barriers and motivators to voluntary medical male circumcision uptake among different age groups of men in Zimbabwe: results from a mixed methods study. PLoS ONE. 2014;9(5): e83998. doi: 10.1371/journal.pone.0085051

18. Macintyre K, Andrinopoulos K, Moses N, Bornstein M, Ochieng A, Peacock E, et al. Attitudes, perceptions and potential uptake of male circumcision among older men in Turkana County, Kenya using qualitative methods. PLoS ONE. 2014; 9(5): e83998. doi: 10.1371/journal.pone.0083998 24802112

19. Njeuhmeli E, Hatzold K, Gold E, Mahler H, Kripke K, Seifert-Ahanda K, et al. Lessons learned from scale-up of voluntary medical male circumcision focusing on adolescents: benefits, challenges, and potential opportunities for linkages with adolescent HIV, sexual, and reproductive health services. J Acquir Immune Defic Syndr. 2014. Jul 1:66 Supple 2: S193–9. doi: 10.1097/QAI.0000000000000179

20. Centers for Disease Control and Prevention (CDC). Voluntary medical male circumcision: southern and eastern Africa, 2010–2012. MMWR. 2013; 62(47): 953–7. 24280914

21. Binagwaho A, Pegurri E, Muita J, and Bertozzi S. Male circumcision at different ages in Rwanda: A cost-effectiveness study. PLoS Med. 2010;7(1): e1000211. doi: 10.1371/journal.pmed.1000211 20098721

22. Stover J, Kripke K. Estimating the Effects of Targeting Voluntary Medical Male Circumcision Programs to Different Age Groups: The Decision Makers Program Planning Toolkit (DMPPT 2.0). Washington, D.C.: Health Policy Project; 2014.

23. Stover J, et al. Updates to the Spectrum model to estimate key HIV indicators for adults and children. AIDS. 2014; 28(Suppl 4): S427–34. doi: 10.1097/QAD.0000000000000483 25406748

24. Awad S, Sgaier S, Tambatamba B, Mohamoud Y, Lau F, Reed J, et al. Investigating Voluntary Medical Male Circumcision Program Efficiency Gains through Sub-population Prioritization: Insights from Application to Zambia. PLoS ONE. 2015;10(12): e0145729. doi: 10.1371/journal.pone.0145729 26716442

25. Actuarial Society of South Africa (ASSA). ASSA2008 AIDS and Demographic Models–User Guide (beta version). Cape Town: ASSA; 2011.

26. Actuarial Society of South Africa (ASSA). Note to users of the ASSA2008 AIDS and Demographic Model, 27 August 2012. Cape Town: ASSA; 2012.

27. South African National AIDS Council (SANAC). National strategic plan on HIV, STIs and TB 2012–2016. Pretoria: SANAC; 2011. http://www.sahivsoc.org/upload/documents/National_Strategic_Plan_2012.pdf.

28. Guthrie T, Ndlovu N, Muhib F, Hecht R, Case K. Long-run costs and financing of HIV/AIDS in South Africa. Washington, D.C.: Results for Development Institute; 2010.

29. Meyer-Rath G. National ART cost model, South Africa. Health Economics and Epidemiology Research Office, Boston University and University of the Witwatersrand, Johannesburg; 2015.

30. Lule E and Haacker M. The Fiscal Dimension of HIV/AIDS. Washington, D.C.: World Bank; 2012.

31. Joint United Nations Programme on HIV/AIDS (UNAIDS). South Africa HIV/AIDS Spectrum country file 2014. Geneva: UNAIDS; 2014.

32. Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser O. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10(4): e1001418. doi: 10.1371/journal.pmed.1001418 23585736

33. Haacker M. The Economics of the Global Response to HIV/AIDS. Oxford and New York: Oxford University Press; 2016.

34. Hallett T, Alsallaq R, Baeten J, Weiss H, et al. 2011, Will Circumcision Provide Even More Protection from HIV to Women and Men? New Estimates of the Population Impact of Circumcision Interventions. Sexually Transmitted Infections; 87(2): 88–93. doi: 10.1136/sti.2010.043372 20966458